Citius Oncology (CTOR) AI Stock Analysis

• Market Cap: $103.28M
• Dividend Yield: N/A
• Average Volume (3M): 234.01K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.56
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): -0.06
• Shares Outstanding: 88,275,210
• 10 Day Avg. Volume: 272,668
• 30 Day Avg. Volume: 234,012
• PEG Ratio: -0.45
• Price to Book (P/B): 3.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -27.08
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: 24.18
• Enterprise Value/Gross Profit: 30.23
• Enterprise Value/Ebitda: -4.39
• 1Y Price Target: $6.00
• Price Target Upside: 460.75% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $1.00 ▼(-6.54% Downside)
• Action: Reiterated Date: 12/30/25
• Date: Action: Reiterated 12/30/25

The score is primarily weighed down by weak financial performance (pre-revenue, widening losses, and increasing cash burn) and bearish technicals (below key moving averages with negative MACD). Positive corporate events—commercial launch of LYMPHIR and added funding—provide support but do not fully offset profitability and financing risks.

Positive Factors

FDA-approved product launch

FDA approval and commercial launch of LYMPHIR is a structural milestone that moves the company from purely clinical-stage toward commercial-stage. This provides a clear path to initial revenue, supports building a commercial infrastructure, and enhances partnership or licensing prospects over the coming months.

Low leverage

Relatively low debt and a modest debt-to-equity profile give Citius financial flexibility to fund near-term commercialization and R&D without heavy interest burdens. This structural balance sheet strength reduces immediate solvency risk and supports strategic options over the medium term.

Recent committed financing

The ~$18M financing materially extends runway for commercial launch activities and general corporate purposes. This capital provides time to scale sales efforts, collect early-market data, and pursue partnering discussions, making execution of commercialization plans more feasible over the next several months.

Negative Factors

Pre-revenue with widening losses

Remaining pre-revenue while losses have materially increased signals a prolonged path to profitability. Expanding operating losses erode equity and raise the likelihood the company must secure additional funding before meaningful product sales ramp, increasing structural execution and financing risk.

Negative operating and free cash flow

Worsening operating cash flow and larger negative free cash flow indicate growing cash burn that must be funded externally. Structurally, persistent negative cash generation compresses strategic optionality, raises dilution risk, and can force concessions in future financings if sales do not materialize quickly.

Financing terms and dilution risk

Warrant repricing and amended debt terms suggest financings required investor concessions, creating potential equity overhang and dilution. Structurally, reliance on such transactions can depress shareholder value and signal tougher future financing conditions if commercialization cash flows fall short.

Citius Oncology Business Overview & Revenue Model

Company Description

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

How the Company Makes Money

Citius Oncology makes money primarily through the research, development, and commercialization of its cancer treatment drugs. The company's revenue streams include licensing agreements, where it partners with other pharmaceutical companies to co-develop or distribute its products, and sales of approved therapies. Additionally, Citius Oncology may receive milestone payments and royalties from partnerships and collaborations with other entities in the healthcare sector. The company's earnings are influenced by the successful clinical trials and regulatory approval of its drug candidates, as well as strategic partnerships that enhance its market reach.

Citius Oncology Financial Statement Overview

Summary

Overall financial quality is weak: the company is pre-revenue with materially widening losses and rising cash burn (operating cash flow turned meaningfully negative and free cash flow worsened). The main positive is low leverage, but shrinking equity and ongoing losses increase funding risk.

Income Statement

CTOR remains a pre-revenue oncology company (revenue is $0 across all annual periods provided), so operating losses drive results. Losses have widened materially, with EBIT declining from about -$4.9M (2022) to -$23.5M (2025 annual), and net income also deteriorating to about -$24.8M (2025 annual) versus -$5.4M (2022). With no revenue base yet, profitability and margin indicators are not meaningful, and the trajectory points to rising spend ahead of commercialization.

Balance Sheet

The balance sheet shows relatively low leverage, with total debt of about $3.8M in 2024–2025 annual and a low debt-to-equity ratio (~0.08–0.09), which is a positive for financial flexibility. However, equity has drifted down (from ~$46.1M in 2024 to ~$44.9M in 2025 annual), consistent with ongoing losses, and returns on equity are deeply negative (roughly -46% to -55% in 2024–2025 annual). Total assets increased to ~$100.9M in 2025 annual, but the key risk is continued equity erosion if losses persist.

Cash Flow

Cash generation is weak and worsening. Operating cash flow swung from slightly positive in 2024 annual (~$0.1M) to meaningfully negative in 2025 annual (~-$5.5M), and free cash flow is consistently negative, expanding to ~-$11.2M in 2025 annual from ~-$4.9M in 2024 annual. While free cash flow can diverge from net losses due to timing and non-cash items, the overall pattern indicates increasing cash burn, which raises the likelihood of future financing needs absent a revenue inflection.

Breakdown	TTM	Sep 2025	Sep 2024	Sep 2023	Sep 2022
Income Statement
Total Revenue	3.94M	0.00	0.00	0.00	0.00
Gross Profit	3.15M	0.00	0.00	0.00	0.00
EBITDA	-21.74M	-23.49M	-20.57M	-12.12M	0.00
Net Income	-23.64M	-24.76M	-21.15M	-12.70M	-10.87M
Balance Sheet
Total Assets	109.97M	100.94M	84.37M	47.73M	42.69M
Cash, Cash Equivalents and Short-Term Investments	7.30M	3.92M	112.00	0.00	0.00
Total Debt	3.80M	3.80M	3.80M	0.00	0.00
Total Liabilities	51.56M	56.08M	38.23M	22.20M	6.42M
Stockholders Equity	58.41M	44.87M	46.14M	25.54M	36.27M
Cash Flow
Free Cash Flow	-12.89M	-5.49M	126.35K	-601.30K	-47.97K
Operating Cash Flow	-12.89M	-5.49M	126.35K	-601.30K	-47.97K
Investing Cash Flow	-10.19M	-5.75M	-5.00M	-1.32M	-67.32M
Financing Cash Flow	30.41M	15.17M	4.87M	1.66M	67.66M

Citius Oncology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.07
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTOR, the sentiment is Negative. The current price of 1.07 is below the 20-day moving average (MA) of 1.13, below the 50-day MA of 1.13, and below the 200-day MA of 1.62, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 51.82 is Neutral, neither overbought nor oversold. The STOCH value of 60.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTOR.

Citius Oncology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GRFS	72 Outperform	$8.10B	15.83	6.93%	1.56%	9.45%	167.00%
BIIB	64 Neutral	$28.49B	21.81	7.39%	―	5.00%	-1.03%
OGN	59 Neutral	$1.94B	10.36	―	4.80%	-1.69%	-61.89%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CTOR	45 Neutral	$103.28M	-3.93	―	―	―	―
SRXH	42 Neutral	$40.11M	0.05	―	―	-8.12%	―

Citius Oncology Corporate Events

Citius Oncology Raises $18M Through Direct Offering

On December 8, 2025, Citius Oncology entered into a securities purchase agreement with an institutional investor for a registered direct offering and a concurrent private placement, raising approximately $18 million. The proceeds will support the commercial launch of LYMPHIR and general corporate purposes. The offering closed on December 10, 2025, with H.C. Wainwright & Co. acting as the exclusive placement agent. The company also amended existing warrants to reduce exercise prices and adjusted the maturity of a promissory note with Citius Pharmaceuticals.

The most recent analyst rating on (CTOR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.

Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma

On December 1, 2025, Citius Oncology announced the commercial launch of LYMPHIR, a novel IL-2 receptor-directed fusion protein approved by the FDA for treating adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma. This launch marks a significant milestone for the company, enhancing its industry positioning by providing a new treatment option in a competitive landscape and potentially improving patient outcomes.

The most recent analyst rating on (CTOR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.